Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Originally developed to treat type 2 diabetes and medical obesity, GLP-1 receptor agonists like tirzepatide and semaglutide ...

Novo Nordisk (NVO) offered investors an update about ongoing cost-cutting efforts as copycat weight-loss drugs weigh on sales ...

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...

Sales of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro in India doubled in July, according to Pharmarack data. Wegovy, ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.

China has massive unmet medical needs, Mike Doustdar, who took over as CEO of Novo Nordisk today, after previously leading ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit on Wednesday, but rising competition is weighing on sales of its diabetes and obesity treatments Ozempic and ...